201677-57-8

Basic information

• Product Name: ForMaMide, N-[5-(2R)-oxiranyl-2-(phenylMethoxy)phenyl]-
• Synonyms: ForMaMide, N-[5-(2R)-oxiranyl-2-(phenylMethoxy)phenyl]-;N-[2-(benzyloxy)-5-[(2R)-oxiran-2-yl]phenyl]formamide
• CAS NO: 201677-57-8
• Molecular Formula: C₁₆H₁₅NO₃
• Molecular Weight: 269.2952
• Mol File: 201677-57-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ForMaMide, N-[5-(2R)-oxiranyl-2-(phenylMethoxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: ForMaMide, N-[5-(2R)-oxiranyl-2-(phenylMethoxy)phenyl]-(201677-57-8)
• EPA Substance Registry System: ForMaMide, N-[5-(2R)-oxiranyl-2-(phenylMethoxy)phenyl]-(201677-57-8)

Safety Data

• Hazardous Substances Data: 201677-57-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Formamide, N-[5-(2R)-oxiranyl-2-(phenylmethoxy)phenyl]is used as a building block in organic synthesis for its ability to participate in various chemical reactions due to the presence of the oxirane and phenylmethoxy groups. Formamide, N-[5-(2R)-oxiranyl-2-(phenylmethoxy)phenyl]can be employed in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Precursor Synthesis:
Formamide, N-[5-(2R)-oxiranyl-2-(phenylmethoxy)phenyl]is used as a precursor for the synthesis of other complex organic molecules with diverse properties and functionalities. The reactivity of the oxirane group and the presence of the phenyl ring make it a versatile starting material for the development of new compounds with potential applications in various industries.
Used in Chemical Research:
Formamide, N-[5-(2R)-oxiranyl-2-(phenylmethoxy)phenyl]is used in chemical research to explore its reactivity and potential applications. Further research and testing are required to determine the specific uses and potential hazards of this chemical, as well as to optimize its synthesis and application processes.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Formamide, N-[5-(2R)-oxiranyl-2-(phenylmethoxy)phenyl]is used as an intermediate in the synthesis of drug candidates. Its unique structure and reactivity make it a promising candidate for the development of new drugs with novel mechanisms of action.
Used in Material Science:
In the field of material science, Formamide, N-[5-(2R)-oxiranyl-2-(phenylmethoxy)phenyl]is used in the development of new materials with specific properties. Formamide, N-[5-(2R)-oxiranyl-2-(phenylmethoxy)phenyl]-'s reactivity and functional groups can be exploited to create materials with tailored characteristics for various applications, such as coatings, adhesives, or polymers.

Upstream product

• 201677-59-0 N-[5-((1R)-2-bromo-1-hydroxyethyl)-2-(phenylmethoxy)phenyl]carboxamide 
• 6322-56-1 4'-hydroxy-3'-nitroacetophenone 
• 14347-05-8 4-benzyloxy-3-nitroacetophenone 
• 43229-01-2 4-benzyloxy-3-nitrophenacyl bromide 
• 100-44-7 benzyl chloride 
• 188690-82-6 (R)-2-bromo-1-(4-benzyloxy-3-nitrophenyl)ethanol 
• 333796-54-6 (1R)-1-[3-amino-4-(phenylmethoxy)phenyl]-2-bromoethan-1-ol 
• 64-18-6 formic acid 

Downstream Products

• 1173165-40-6 C₃₈H₄₅N₃O₅ 
• 960398-10-1 (4-(4-(4-(2-(4-benzyloxy-3-formylaminophenyl)-2(R)-hydroxyethylamino)butyl)phenyl)butyl)carbamic acid benzyl ester 
• 686780-68-7 {5-{(1R)-2-[bis(phenylmethyl)amino]-1-hydroxyethyl}-2-[(phenylmethyl)oxy]phenyl}formamide 
• 530084-84-5 C₄₅H₄₅N₃O₄ 
• 463934-72-7 N-[5-((1R)-2-{benzyl[6-(but-3-ynyloxy)hexyl]amino}-1-hydroxyethyl)-2-(benzyloxy)phenyl]formamide 
• 1316100-17-0 (R,R)-N-(2-benzyloxy-5-{1-hydroxy-2-[[2-(4-methoxy-phenyl)-1-methyl-ethyl]-(1-phenyl-ethyl)-amino]-ethyl}-phenyl)-formamide 
• 1361398-82-4 N-(5-(2-((2-(4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,6,7,8,8a-hexahydrophthalazin-2(1H)-yl)butyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)formamide 
• 188690-83-7 N-[5-[(1R)-Hydroxy-2-[[(1R)-methyl-2-(4-methoxyphenyl)ethyl](phenylmethyl)amino]ethyl]-2-(phenylmethoxy)phenyl]-formamide 
• 73573-87-2 (R,R)-formoterol 

Relevant articles and documents

Method for synthesizing arformoterol free alkali

The invention discloses a method for synthesizing arformoterol free alkali, which comprises the following steps of: (1) performing carbonyl chiral reduction reaction on a compound shown as a formula SM1 serving as a raw material in a first solvent to obtain a reaction solution containing a compound shown as a formula M1, and concentrating to dryness; (2) dissolving the material obtained in the step (1) with a second solvent, carrying out a hydrogenation reaction to obtain a reaction liquid containing a compound represented by a formula M2, filtering the reaction liquid, and cooling the filtrate; (3) carrying out formylation reaction on the filtrate cooled in the step (2) to obtain a reaction solution containing a compound as shown in a formula M3, and concentrating to dryness; (4) dissolving the material obtained in the step (3) with a third solvent, carrying out a cyclization reaction to obtain a reaction liquid containing a compound represented by a formula M4 and free SM2, filtering, and concentrating the filtrate to dryness; and (5) dissolving the material obtained in the step (4) with a fourth solvent, carrying out a condensation reaction to obtain an arformoterol precursor represented by a formula M5, and carrying out hydrogenation debenzylation on the M5 to obtain arformoterol.

PROCESS FOR THE PREPARATION OF ARFORMOTEROL OR SALT THEREOF

Provided is an improved process for the preparation of arformoterol L-(+)-tartrate, and more specifically provided is a novel process for the preparation of arformoterol L-(+)-tartrate via arformoterol D-(?)-tartrate.

Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD

We designed and synthesized a novel class of dual pharmacology bronchodilators targeting both b2-adrenoceptor and PDE4 by applying a multivalent approach. The most potent dual pharmacology molecule, compound 29, possessed good inhibitory activity on PDE4B2 (IC50 = 0.278 μM, which was more potent than phthalazinone, IC50 = 0.520 lM) and possessed excellent relaxant effects on tracheal rings precontracted by histamine (pEC50 = 9.3).

The asymmetric synthesis of (R,R)-formoterol via transfer hydrogenation with polyethylene glycol bound Rh catalyst in PEG2000 and water

(R,R)-formoterol was synthesized in seven steps with 4-hydroxyl-3-nitro- acetophenone as the starting material. The key intermediate, the chiral secondary alcohol 4, was prepared via Rh-catalyzed asymmetric transfer hydrogenation with (S,S)-PEGBsDPEN as the ligand and sodium formate as the hydrogen donor under mild conditions. With a mixture of PEG 2000 and water as the reaction media, the catalyst system could be recycled four times.

PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

Large-scale synthesis of enantio- and diastereomerically pure (R,R)-formoterol

(R,R)-Formoterol (1) is a long-acting, very potent β2-agonist, which is used as a bronchodilator in the therapy of asthma and chronic bronchitis. Highly convergent synthesis of enantio- and diastereomerically pure (R,R)-formoterol fumarate is achieved by a chromatography-free process with an overall yield of 44%. Asymmetric catalytic reduction of bromoketone 4 using as catalyst oxazaborolidine derived from (1R, 2S)-1-amino-2-indanol and resolution of chiral amine 3 are the origins of chirality in this process. Further enrichment of enantio- and diastereomeric purity is accomplished by crystallizations of the isolated intermediates throughout the process to give (R,R)-formoterol (1) as the pure stereoisomer (ee, de >99.5%).